Ionic derivatives of betulinic acid as novel HIV-1 protease inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 27, Issue 5, 2012, Pages 715-721

  Zhao, Hua ^a   Holmes, Shaletha S ^a   Baker, Gary A ^b   Challa, Suresh ^a,c   Bose, Himangshu S ^d   Song, Zhiyan ^a  

^a SAVANNAH STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c NATIONAL INSTITUTE OF NUTRITION   (India)

^d MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti HIV; Betulinic acid; Derivative; HIV 1 protease; Ionic liquid

Indexed keywords

BETULIC ACID; BETULINIC ACID GLYCINE CHOLINIUM SALT; CHOLINIUM BETULINATE; GLYCINYLATED BETULINIC ACID BENZALKONIUM SALT; HUMAN IMMUNODEFICIENCY VIRUS 1 PROTEINASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DERIVATIZATION; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROLYSIS; PRIORITY JOURNAL;

CATALYSIS; GLYCINE; HIV PROTEASE; HIV PROTEASE INHIBITORS; HYDROLYSIS; IONS; MAGNETIC RESONANCE SPECTROSCOPY; SOLUBILITY; TRITERPENES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84866105934     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.611134     Document Type: Article

References (46)

1. Yogeeswari P, Sriram D. Betulinic acid and its derivatives: A review on their biological properties. Curr Med Chem 2005;12:657-666. (Pubitemid 40331058)
2. Krasutsky PA. Birch bark research and development. Nat Prod Rep 2006;23:919-942. (Pubitemid 44808994)
3. Baglin I, Mitaine-Offer AC, Nour M, Tan K, Cavé C, Lacaille-Dubois MA. A review of natural and modified betulinic, ursolic and echinocystic acid derivatives as potential antitumor and anti-HIV agents. Mini Rev Med Chem 2003;3:525-539.
4. Aiken C, Chen CH. Betulinic acid derivatives as HIV-1 antivirals. Trends Mol Med 2005;11:31-36. (Pubitemid 40092672)
5. Fujioka T, Kashiwada Y, Kilkuskie RE, Cosentino LM, Ballas LM, Jiang JB et al. Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod 1994;57:243-247.
6. Kashiwada Y, Hashimoto F, Cosentino LM, Chen CH, Garrett PE, Lee KH. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J Med Chem 1996;39:1016-1017. (Pubitemid 26082932)
7. Kashiwada Y, Wang HK, Nagao T, Kitanaka S, Yasuda I, Fujioka T et al. Anti-AIDS agents. 30. Anti-HIV activity of oleanolic acid, pomolic acid, and structurally related triterpenoids. j Nat Prod 1998;61:1090-1095. (Pubitemid 28464734)
8. Kashiwada Y, Chiyo J, Ikeshiro Y, Nagao T, Okabe H, Cosentino LM et al. Synthesis and anti-HIV activity of 3-alkylamido-3-deoxybetulinic acid derivatives. Chem Pharm Bull 2000;48:1387-1390.
9. Kanamoto T, Kashiwada Y, Kanbara K, Gotoh K, Yoshimori M, Goto T et al. Anti-human immunodeficiency virus activity of YK-FH312 a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother 2001;45:1225-1230. (Pubitemid 32231004)
10. Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, Lee KH et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. j Virol 2004;78:922-929. (Pubitemid 38067613)
11. Mayaux JF, Bousseau A, Pauwels R, Huet T, Hénin Y, Dereu N et al. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc Natl Acad Sci usa 1994;91:3564-3568. (Pubitemid 24139470)
12. Evers M, Poujade C, Soler F, Ribeill Y, James C, Lelièvre Y et al. Betulinic acid derivatives: A new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action. j Med Chem 1996;39:1056-1068. (Pubitemid 26082939)
13. Soler F, Poujade C, Evers M, Carry JC, Hénin Y, Bousseau A et al. Betulinic acid derivatives: A new class of specific inhibitors of human immunodeficiency virus type 1 entry. j Med Chem 1996;39:1069-1083. (Pubitemid 26082940)
14. Labrosse B, Pleskoff O, Sol N, Jones C, Hénin Y, Alizon M. Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41. j Virol 1997;71:8230-8236. (Pubitemid 27446398)
15. Holz-Smith SL, Sun IC, Jin L, Matthews TJ, Lee KH, Chen CH. Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564. Antimicrob Agents Chemother 2001;45:60-66. (Pubitemid 32039094)
16. Bär S, Alizon M. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process. j Virol 2004;78:811-820. (Pubitemid 38067603)
17. Pengsuparp T, Cai L, Fong HH, Kinghorn AD, Pezzuto JM, Wani MC et al. Pentacyclic triterpenes derived from Maprounea africana are potent inhibitors of HIV-1 reverse transcriptase. j Nat Prod 1994;57:415-418. (Pubitemid 24123512)
18. Ma C, Nakamura N, Miyashiro H, Hattori M, Shimotohno K. Inhibitory effects of constituents from Cynomorium songaricum and related triterpene derivatives on HIV-1 protease. Chem Pharm Bull 1999;47:141-145. (Pubitemid 29114049)
19. Quéré L, Wenger T, Schramm HJ. Triterpenes as potential dimerization inhibitors of HIV-1 protease. Biochem Biophys Res Commun 1996;227:484-488. (Pubitemid 26362830)
20. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005;11:1805-1843 (Pubitemid 40668138)
21. Mastrolorenzo A, Rusconi S, Scozzafava A, Barbaro G, Supuran CT. Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr Med Chem 2007;14:2734-2748. (Pubitemid 350130917)
22. Jäger S, Winkler K, Pfüller U, Scheffler A. Solubility studies of oleanolic acid and betulinic acid in aqueous solutions and plant extracts of Viscum album L. Planta Med 2007;73:157-162. (Pubitemid 46910434)
23. Zhao H, Jones CL, Cowins JV. Lipase dissolution and stabilization in ether-functionalized ionic liquids. Green Chem 2009;11: 1128-1138.
24. Mukherjee R, Kumar V, Srivastava SK, Agarwal SK, Burman AC. Betulinic acid derivatives as anticancer agents: structure activity relationship. Anticancer Agents Med Chem 2006;6:271-279. (Pubitemid 43796644)
25. Zhao H, Baker GA, Song Z, Olubajo O, Crittle T, Peters D. Designing enzyme-compatible ionic liquids that can dissolve carbohydrates. Green Chem 2008;10:696-705. (Pubitemid 351782892)
26. Jeong HJ, Chai HB, Park SY, Kim DS. Preparation of amino acid conjugates of betulinic acid with activity against human melanoma. Bioorg Med Chem Lett 1999;9:1201-1204. (Pubitemid 29204685)
27. Hough WL, Rogers RD. Ionic liquids then and now: From solvents to materials to active pharmaceutical ingredients. Bull Chem Soc Jpn 2007;80:2262-2269.
28. Stoimenovski J, MacFarlane DR, Bica K, Rogers RD. Crystalline vs. ionic liquid salt forms of active pharmaceutical ingredients: A position paper. Pharm Res 2010;27:521-526.
29. Bica K, Rijksen C, Nieuwenhuyzen M, Rogers RD. In search of pure liquid salt forms of aspirin: Ionic liquid approaches with acetylsalicylic acid and salicylic acid. Phys Chem Chem Phys 2010;12:2011-2017.
30. Hough WL, Smiglak M, Rodríguez H, Swatloski RP, Spear SK, Daly DT, Pernak J, Grisel JE, Carliss RD, Soutullo MD et al. The third evolution of ionic liquids: Active pharmaceutical ingredients. New J Chem 2007;31:1429-1436. (Pubitemid 47174172)
31. Ho PT, Ngu K-y. An effective synthesis of N-(9- fluorenylmethyloxycarbonyl) α-amino aldehydes from S-benzyl thioesters. J Org Chem 1993;58:2313-2316.
32. Ammazzalorso A, Amoroso R, Bettoni G, De Filippis B, Giampietro L, Pierini M, Tricca ML. Asymmetric synthesis of (S)-ibuprofen by esterification with amides of (S)-lactic acid as chiral auxiliaries: Experimental and theoretical results. Tetrahedron Lett 2002;43:4325-4328. (Pubitemid 34651709)
33. Rodrigues PC, Roth T, Fiebig HH, Unger C, Mülhaupt R, Kratz F. Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity. Bioorg Med Chem 2006;14:4110-4117.
34. Dinarès I, de Miguel CG, Ibáñez A, Mesquida N, Alcalde E. Imidazolium ionic liquids: A simple anion exchange protocol. Green Chem 2009;11:1507-1510.
35. Zhao H, Baker GA, Holmes S. New eutectic ionic liquids for lipase activation and enzymatic preparation of biodiesel. Org Biomol Chem 2011;9:1908-1916.
36. Richards AD, Phylip LH, Farmerie WG, Scarborough PE, Alvarez A, Dunn BM et al. Sensitive, soluble chromogenic substrates for HIV-1 proteinase. j Biol Chem 1990;265:7733-7736.
37. Porter DJ,Hanlon MH,Carter LH3rd, Danger DP, Furfine ES. Effectors of HIV-1 protease peptidolytic activity. Biochemistry 2001;40:11131-11139. (Pubitemid 32847981)
38. Chinchilla R, Nájera C, Yus M, Heumann A. Kinetic resolution of racemic carboxylic acids with homochiral alcohols and dicyclohexylcarbodiimide. Tetrahedron: Asymmetry 1991;2: 101-104.
39. Blusztajn JK. Choline, a vital amine. Science 1998;281:794-795. (Pubitemid 28376032)
40. Dunn BM, Kammermann B, McCurry KR. The synthesis, purification, and evaluation of a chromophoric substrate for pepsin and other aspartyl proteases: design of a substrate based on subsite preferences. Anal Biochem 1984;138:68-73.
41. Dunn BM, Jimenez M, Parten BF, Valler MJ, Rolph CE, Kay J. A systematic series of synthetic chromophoric substrates for aspartic proteinases. Biochem j 1986;237:899-906.
42. Tewtrakul S, Subhadhirasakul S, Rattanasuwan P. HIV-1 protease inhibitory effects of some selected plants in Caesalpiniaceae and Papilionaceae families. Songklanakarin J Sci Technol 2003;25:509-514.
43. Wondrak EM, Louis JM, Oroszlan S. The effect of salt on the Michaelis Menten constant of the HIV-1 protease correlates with the Hofmeister series. FEBS Lett 1991;280:344-346.
44. Gruber A, Wheat JC, Kuhen KL, Looney DJ, Wong-Staal F. Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function. j Biol Chem 2001;276:47840-47843.
45. Min BS, Bae KH, Kim YH, Miyashiro H, Hattori M, Shimotohno K. Screening of Korean plants against human immunodeficiency virus type 1 protease. Phytother Res 1999;13:680-682.
46. Wu X, Ohrngren P, Ekegren JK, Unge J, Unge T, Wallberg H et al. Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol- containing transition-state mimic. j Med Chem 2008;51:1053-1057 (Pubitemid 351304714)